Abstract
Introduction
The complexity of chemotherapy protocols and the narrow therapeutic index of anticancer drugs make the risk of medication errors particularly high in oncology. This study analyzed and categorized pharmaceutical interventions related to chemotherapy prescriptions in a clinical hematology center.
Methods
This study was conducted in a specialized clinical hematology center over a defined study period (16 months). All chemotherapy prescriptions validated by clinical pharmacists were reviewed. Validation was performed according to both regulatory and scientific criteria. Identified therapy-related problems were discussed with physicians, and all pharmaceutical interventions were recorded and classified according to the ReMeD severity scale.
Results
A total of 6186 chemotherapy prescriptions were analyzed, leading to 117 pharmaceutical interventions. The most common errors involved dosage errors (n = 51;49.03%), omission of prescription (n = 23;22.11%) and incorrect treatment duration (n = 11;10.57%). Most interventions were rated as having a major clinical impact, particularly those preventing omission and posology errors, ensuring optimal chemotherapy management and patient safety. All interventions were accepted by physicians, highlighting strong interdisciplinary collaboration.
Conclusion
Pharmaceutical interventions represent a key component in improving the safety and quality of chemotherapy management. Strengthening the pharmacist's integration into oncology teams ensures better therapeutic outcomes, reduces medication-related risks, and supports a culture of safe and evidence-based cancer care.
Get full access to this article
View all access options for this article.